4D Molecular Therapeutics Inc. (FDMT) is heading in the right direction with an average volume of $490.53K


4D Molecular Therapeutics Inc. (NASDAQ: FDMT) started the day on November 23, 2022, with a price decrease of -1.02% at $23.26. During the day, the stock rose to $24.21 and sunk to $22.7158 before settling in for the price of $23.50 at the close. Taking a more long-term approach, FDMT posted a 52-week range of $5.32-$24.82.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


Nevertheless, stock’s Earnings Per Share (EPS) this year is -21.00%. This publicly-traded company’s shares outstanding now amounts to $32.39 million, simultaneously with a float of $28.66 million. The organization now has a market capitalization sitting at $767.58 million. At the time of writing, stock’s 50-day Moving Average stood at $10.15, while the 200-day Moving Average is $10.63.

It is quite necessary to find out the efficiency of the corporate organization, which has 140 number of employees on its payroll. For the Profitability, stocks gross margin was +83.26, operating margin was -395.46 and Pretax Margin of -395.37.

4D Molecular Therapeutics Inc. (FDMT) Ownership Facts and Figures

Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. 4D Molecular Therapeutics Inc.’s current insider ownership accounts for 11.51%, in contrast to 82.30% institutional ownership.

4D Molecular Therapeutics Inc. (FDMT) Earnings and Revenue Records

In the latest quarterly report released, which was put into the public domain on 6/29/2022, the organization reported -$0.87 earnings per share (EPS) for the three months, lower than the consensus estimate (set at -$0.85) by -$0.02. This company achieved a net margin of -395.37 while generating a return on equity of -24.78. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.

4D Molecular Therapeutics Inc.’s EPS decrease for this current 12-month fiscal period is -21.00% and is forecasted to reach -3.66 in the upcoming year.

4D Molecular Therapeutics Inc. (NASDAQ: FDMT) Trading Performance Indicators

Let’s observe the current performance indicators for 4D Molecular Therapeutics Inc. (FDMT). It’s Quick Ratio in the last reported quarter now stands at 17.10. The Stock has managed to achieve an average true range (ATR) of 2.09. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 383.79.

In the same vein, FDMT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.30, a figure that is expected to reach -0.80 in the next quarter, and analysts are predicting that it will be -3.66 at the market close of one year from today.

Technical Analysis of 4D Molecular Therapeutics Inc. (FDMT)

If we take a close look at the recent performances of 4D Molecular Therapeutics Inc. (NASDAQ: FDMT), its last 5-days Average volume was 1.18 million that shows progress from its year to date volume of 0.3 million. During the previous 9 days, stock’s Stochastic %D was recorded 86.14% While, its Average True Range was 2.43.


Please enter your comment!
Please enter your name here